Showing 561-570 of 5061 results for "".
- Novan, Inc. Acquires EPI Healthhttps://practicaldermatology.com/news/novan-inc-acquires-epi-health/2461106/EPI Health is now a Novan Company. The EP Group today announced the acquisition of EPI Health, LLC by Novan, Inc. EPI Health is a leading company in the US dermatology sector with an established sales force and commercial team with existing, deep market relationships across the de
- Study: Melanoma Referral Centers Worldwide Adopt Systemic Therapies, Reduce Lymph Node Removal Surgerieshttps://practicaldermatology.com/news/study-melanoma-referral-centers-worldwide-adopt-systemic-therapies-reduce-lymph-node-removal-surgeries/2461097/Lymph node removal surgery for patients with high-risk melanoma has become less common over the past few years while the use of targeted and immune therapies has risen rapidly at melanoma referral centers worldwide, an international group of researchers found. However, a large degree of
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training
- ASDS Survey Highlights Teledermatology Boom, Staffing Challenges, and Other Ways COVID-19 Upended Practicehttps://practicaldermatology.com/news/asds-survey-sites-teledermatology-boom-staffing-challenges-and-other-ways-pandemic-upended-practice/2461070/From dramatic upticks in the use of teledermatology to staffing challenges and delays in procedures, the ongoing COVID-19 pandemic continues to affect dermatology practices and patients, according to a
- Phase 3 Data Show Benefit of Dupixent to Reduce Itch in Prurigo Nodularishttps://practicaldermatology.com/news/phase-3-data-show-benefit-of-dupixent-to-reduce-itch-in-prurigo-nodularis/2461044/Dupixent® (dupilumab) from Sanofi and Regeneron significantly reduced itch and skin lesions compared to placebo at 24 weeks in a phase 3 trial in adults with uncontrolled prurigo nodularis. The new data confirm positive results
- Scleroderma Research Foundation Announces $1.5M Matching Gift in Honor of Bob Sagethttps://practicaldermatology.com/news/scleroderma-research-foundation-announces-15m-matching-gift-in-honor-of-bob-saget/2461035/The Scleroderma Research Foundation (SRF) announced a $1.5M matching gift in honor of Bob Saget, a SRF
- Rinvoq Scores FDA Nod for Active Psoriatic Arthritishttps://practicaldermatology.com/news/rinvoq-scores-us-fda-nod-for-active-psoriatic-arthritis/2461012/The U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. "The efficacy
- Novel Lyme Vaccine Shows Promise in Early Researchhttps://practicaldermatology.com/news/novel-lyme-vaccine-shows-promise-in-early-research/2460994/Yale University researchers have developed a novel vaccine that in guinea pigs offers protection against infection by the bacterium that causes Lyme disease and may also combat other tick-borne diseases, they report in the journal Science Translational Medicine. Instead of trig
- Nearly One Third of Lupus Patients Show Low Responses to COVID-19 Vaccineshttps://practicaldermatology.com/news/nearly-one-third-of-lupus-patients-show-low-responses-to-covid-19-vaccines/2460980/Nearly 30 percent of lupus patients with had a low response to the new COVID-19 vaccines, finds research presented at ACR Convergence, the American College of Rheumatology’s annual meeting. Since Phase III clinical trials of COVID-19 vaccines excluded people who take im
- Dupixent Reduces Itch, Clears Skin in Prurigo Nodularis Phase 3 Trialhttps://practicaldermatology.com/news/dupixent-reduces-itch-clears-skin-in-prurigo-nodularis-phase-3-trial/2460969/Data from a pivotal Phase 3 trial show that Dupixent® (dupilumab) reduced itch and led to higher rates of skin clearance than placebo among adults with uncontrolled prurigo nodularis. In the Phase 3 PRIME2 trial, 37 percent of Dupixent